High-molecular anti-tumor medicine for bonding vascular disrupting agent and immunomodulatory agent and preparation method thereof

A technology of vascular blockers and immunomodulators, which is applied in the direction of antineoplastic drugs, drug combinations, and pharmaceutical formulations, can solve the problems of easy recurrence, metastasis, and spread of tumors, drug resistance, and unsatisfactory clinical chemotherapy effects, and improve the efficacy of drugs Problems, inhibition of diffusion transfer, effects of stimulus sensitivity

Active Publication Date: 2019-05-21
XIANGTAN UNIV
View PDF6 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] Aiming at the problems that traditional chemotherapy is prone to drug resistance, chemotherapy drugs cannot penetrate into the tumor, and tumors are pr

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • High-molecular anti-tumor medicine for bonding vascular disrupting agent and immunomodulatory agent and preparation method thereof
  • High-molecular anti-tumor medicine for bonding vascular disrupting agent and immunomodulatory agent and preparation method thereof
  • High-molecular anti-tumor medicine for bonding vascular disrupting agent and immunomodulatory agent and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] 1. Preparation of polyethylene glycol monomethyl ether-b-polylactide:

[0068] Take by weighing 1.0g (4.9mmol) norbornene lactide and 0.8g (0.16mmol) polyethylene glycol monomethyl ether (molecular weight is 5000) in the dry anaerobic ampoule that has baked three times, then in argon Add a catalytic amount of 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD) and 5.0 mL of refined dichloromethane under air protection, and react at room temperature for 48 hours. After the completion, the sedimentation was repeated three times with anhydrous ether, left to stand and centrifuged, and then vacuum-dried to obtain polyethylene glycol monomethyl ether-b-polylactide. Its structural characterization can be seen in the H NMR spectrum figure 1 , Molecular Weight Distribution Plot Figure 7(B), indicating that the polymer has been successfully synthesized.

[0069] 2. Preparation of polyethylene glycol monomethyl ether-b-polylactide containing carboxyl side groups:

[0070] Weigh 1.2g (...

Embodiment 2

[0080] Other experimental steps and experimental conditions are as in Example 1, except that the molar ratio of main chain norbornene lactide and polyethylene glycol monomethyl ether (molecular weight is 5000) is adjusted to 10:1; 20:1; 40:1, Polyethylene glycol monomethyl ether-b-polylactide block polymers with different molecular weights were prepared. Then, the polyethylene glycol monomethyl ether-b-polylactide block polymer was used for subsequent grafting of compretidine and imiquimod, and a drug similar to that of Example 1 was also obtained.

Embodiment 3

[0082] Other steps and experimental conditions are as in Example 1, except that the addition ratio of compretidine containing diphenylcyclooctyne functional group and imiquimod containing diphenylcyclooctyne functional group in the preparation process of polymer bonded drug Adjusted to 7:1; 7:2, the polymer-bonded drugs with different grafting ratios of the two drugs were prepared.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a high-molecular anti-tumor medicine for bonding a vascular disrupting agent and an immunomodulatory agent and a preparation method thereof. According to the high-molecular anti-tumor medicine, a polyethylene glycol block and a polylactide block serve as main chains, and the vascular disrupting agent and immunomodulatory agent pharmaceutical molecules are grafted and bondedat the same time on the main chins through chemical reactions such as a sulfydryl-alkene light click reaction, an esterification reaction and a nitrine-alkyne cyclic addition reaction. Due to the synergistic effect of the tumor vascular occlusion therapy and the immune therapy, the high-molecular anti-tumor medicine improves the anti-cancer activity under the condition that the dosage of the medicine is reduced, and the defects that a traditional chemotherapeutic has difficulty in infiltrating in tumor cells and has drug resistance are avoided; meanwhile, the immune therapy is used for activating the immune system of a patient to kill the tumor cells for a long time, and clinical tumor metastasis and relapse are effectively prevented. In addition, a synthetic method of the anti-tumor polymer bonding medicine has the advantages of being simple, effective, mild in reaction condition and the like.

Description

technical field [0001] The invention relates to a polymer anti-tumor drug, in particular to an anti-tumor polymer-bonded drug simultaneously bonded with a blood vessel blocking agent and an immunomodulator, and a preparation method thereof; belonging to the field of biomedical polymer materials. Background technique [0002] As a global public health problem, tumors have greatly endangered human health, and have become the leading cause of human death in the new century. At present, cancer treatment mainly includes chemotherapy, surgical treatment, radiotherapy and other main methods. Although traditional chemotherapy has been improved for a long time, there are still problems such as the difficulty of anticancer drugs penetrating into the tumor and long-term use to produce drug resistance, which makes the treatment effect not good. Satisfactory, but both radiation therapy and surgical treatment have defects such as high toxicity and side effects, and easy to cause tumor cel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K47/59A61K47/60A61K45/06A61K31/09A61K31/4745A61P35/00
Inventor 张雪飞佘攀
Owner XIANGTAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products